GLPwatch
Papers (12034)
Page 135 of 201, ranked by citation count.
- Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes.
- Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine.
- Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats.
- Use of liraglutide after bariatric surgery: a 36-month follow-up in a real-world setting in Chile.
- Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery.
- Antidiabetic Effect of Abextide, a Long-Acting Exendin-4 Analogue in Cynomolgus Monkeys.
- Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report.
- Liraglutide Treatment Reverses Unconventional Cellular Defects in Induced Pluripotent Stem Cell-Derived β-Cells Harboring a Partially Functional WFS1 Variant.
- Metformin-associated lactic acidosis precipitated by liraglutide use: adverse effects of aggressive antihyperglycaemic therapy.
- Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
- Feasibility of once weekly exenatide-LAR and enhanced diabetes care in Indigenous Australians with type 2 diabetes (Long-acting-Once-Weekly-Exenatide laR-SUGAR, 'Lower SUGAR' study).
- Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.
- Activation of G-protein-coupled receptors and thyroid malignant tumors: the jury is still out.
- Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
- Supramolecular prodrug of SN38 based on endogenous albumin and SN38 prodrug modified with semaglutide side chain to improve the tumor distribution.
- Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases.
- Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1.
- Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.
- New hypoglycemic agents and the kidney: what do the major trials tell us?
- Diabetic ketoacidosis in a patient with type I diabetes treated with tirzepatide.
- Type 2 diabetes: which drug as add-on to metformin?
- Exendin-4 improves resistance to Listeria monocytogenes infection in diabetic db/db mice.
- Instrumental Variable Methods to Target Hypothetical Estimands With Longitudinal Repeated Measures Data: Application to the STEP 1 Trial.
- Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.
- Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.
- Liraglutide modulates morpho-functional and inflammatory gastrointestinal responses in rats.
- In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
- Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial.
- Vitreous hemorrhage during GLP-1 receptor agonist treatment.
- The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
- Understanding the Benefit of Combining GLP-1 Agonists With Exercise: Time Will Tell.
- Liraglutide improved glycaemic instability in a patient with diabetes with insulin antibodies.
- Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-Exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1.
- Sustained metabolic benefits of ΔTRTX-Ac1, a tarantula venom-derived peptide, when administered together with exenatide in high-fat fed mice.
- Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity.
- Metabonomic analysis of the therapeutic effect of exendin-4 for the treatment of tBHP-induced injury in mouse glomerulus mesangial cells.
- Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.
- Non arteritic ischemic optic neuropathy in a patient taking semaglutide: Is there a relation? A case report and a review of the literature.
- A New Drug for Obesity: Tirzepatide.
- Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.
- Weight Loss in Veterans with Schizophrenia and Multimorbidity Prescribed Semaglutide: Results From a National Retrospective Cohort Study.
- How to 'drug' our way out of the obesity crisis (or not): the roll-out of semaglutide.
- Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
- Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway.
- Semaglutide and health risk: Development and validation of a LC-HRMS method for testing semaglutide in whole blood and application to real cases.
- Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.
- The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
- A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.
- Liraglutide, GLP-1 receptor agonist, for chronic weight loss.
- Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.
- The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.
- Semaglutide, Ertugliflozin, and Deflazacort.
- Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies.
- Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.
- A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
- Advancing Diabetes Management and Glycemic Control While Exploring CagriSema's Impact on Obesity Management.
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- Liraglutide upregulates the Cftr gene and regulates the mucus transcriptome profile in Brunner's glands in mice.
- Liraglutide limits the immunogenic cell death-mediated ROS propagation and PI3K/AKT inactivation after doxorubicin-induced gonadotoxicity in rats: Involvement of the canonical Hedgehog trajectory.
- Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.